$SRRK

Burow Kristina sold $164K of SRRK

Burow Kristina sold 3,053 shares of Scholar Rock Holding Corp (SRRK) at an average of $53.74 ($53.49–$54.28, $0.16M total) across 2 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Burow Kristina
Published Jul 6, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 7:48 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SRRK
Neutral
medium confidence
Mentioned
$SRRK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SRRKNeutralLow
01

Why it matters

The disclosure updates the record of insider activity and may influence short-term sentiment, but it does not introduce new fundamentals.

02

Market read

A director’s scheduled insider sale is disclosed, which can slightly affect sentiment but is unlikely to drive a fundamental repricing by itself.

03

What to watch

Traders may overreact to insider selling; the key nuance here is the pre-arranged 10b5-1 structure and the lack of any accompanying company-specific news.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-06 for trades dated 2026-07-01

Background

The article is an SEC Form 4 insider transaction disclosure for Scholar Rock Holding Corp, reported by a director.

Company-level read

Ticker impact

$SRRKNeutralMedium confidence
Context

Scholar Rock director Kristina Burow sold about 3,053 shares in open-market trades under a 10b5-1 plan, totaling $164,063.83.

Expected impact

Likely limited near-term impact; any effect is more about optics than new company information.

Evidence & confidence

The filing discloses the transaction size and timing, but provides no new operational, financial, or regulatory facts about Scholar Rock.

Market effects

No clear sector read-through from a single director 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations, reducing the signal value.

Key entities

  • Scholar Rock Holding Corp

    Subject of the Form 4 insider transaction disclosure.

  • Kristina Burow

    Director who executed open-market sales under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SRRKMedAI 9/10

Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?

Scholar Rock Holding (SRRK) received FDA approval for ISEMBYLD, a treatment for spinal muscular atrophy in patients aged 2+. The drug showed a 2.2-point advantage over placebo in motor ability tests. The company is launching the product in the U.S., with support programs for insurance and infusions. Commercial success depends on patient access and treatment persistence, with safety concerns and reimbursement terms being key factors.

$SRRKMed

SRRK Maintained by Evercore ISI Group -- Price Target Raised to

Evercore ISI Group analyst Cory Kasimov maintained an 'Outperform' rating on Scholar Rock Holding Corp (SRRK) and raised the price target from $65.00 to $72.00, a 10.77% increase. SRRK's current price is $47.34 with a market cap of $5.77 billion. The company's GF Score™ is 29/100, indicating room for improvement in financial metrics. Insider activity shows $923,107 in sales over the last three months. The company focuses on biotechnology, developing therapies for rare neuromuscular diseases.

$SRRKHighAI 9/10

Scholar Rock wins FDA approval for spinal muscle atrophy drug

Scholar Rock received FDA approval for Isembyld, a drug targeting muscle loss in spinal muscular atrophy (SMA). The approval follows successful clinical trials showing improved motor skills in patients. The drug is approved for use with existing SMA therapies. Scholar Rock, valued at $6.8B, addressed manufacturing issues before resubmission. Pricing details are pending.